IUPAC/Chemical Name
Actinomycin D, 7-((hydroxyacetyl)amino)-, ester with L-valine
InChi Key
YSIALVLPAPHPRR-YWCQQVNBSA-N
InChi Code
InChI=1S/C69H98N14O19/c1-29(2)46(70)67(96)99-28-42(84)72-39-25-38(59(88)76-50-36(13)100-68(97)54(32(7)8)80(17)43(85)26-78(15)63(92)40-21-19-23-82(40)65(94)48(30(3)4)74-61(50)90)52-57(34(39)11)102-58-35(12)56(87)47(71)45(53(58)73-52)60(89)77-51-37(14)101-69(98)55(33(9)10)81(18)44(86)27-79(16)64(93)41-22-20-24-83(41)66(95)49(31(5)6)75-62(51)91/h25,29-33,36-37,40-41,46,48-51,54-55H,19-24,26-28,70-71H2,1-18H3,(H,72,84)(H,74,90)(H,75,91)(H,76,88)(H,77,89)/t36-,37-,40-,41-,46+,48-,49-,50+,51+,54-,55+/m1/s1
SMILES Code
C(=O)(OCC(Nc1cc(c2nc3c(c(c(c(C)c3oc2c1C)=O)N)C(=O)N[C@@H]1C(=O)N[C@@H](C(N2[C@@H](C(N(C)CC(N([C@@H](C(C)C)C(=O)O[C@@H]1C)C)=O)=O)CCC2)=O)C(C)C)C(N[C@@H]1C(N[C@@H](C(N2[C@@H](C(N(CC(N([C@@H](C(O[C@@H]1C)=O)C(C)C)C)=O)C)=O)CCC2)=O)C(C)C)=O)=O)=O)[C@@H](N)C(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,427.62
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Moore S, Patel RP, Atherton E, Kondo M, Meienhofer J. Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1. J Med Chem. 1976 Jun;19(6):766-72. PubMed PMID: 950643.
2: Bhuyan BK, Fraser TJ, Day KJ. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2. Cancer Treat Rep. 1976 Dec;60(12):1813-8. PubMed PMID: 1036090.
3: Mikhaĭlov MV, Nikitin SM, Zasedatelev AS, Zhuze AL, Gurskiĭ GV. [Actinomycin D derivatives that recognize 2 DNA GC pairs: bis-actinomycin D]. Dokl Akad Nauk SSSR. 1981;260(1):239-44. Russian. PubMed PMID: 6273089.
4: Culine S, Philippot I, Farhat F, Théodore C, Terrier-Lacombe MJ, Droz JP. Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors. Bull Cancer. 1997 Apr;84(4):368-72. PubMed PMID: 9238159.
5: Nisoli E, Tonello C, Briscini L, Carruba MO. Inducible nitric oxide synthase in rat brown adipocytes: implications for blood flow to brown adipose tissue. Endocrinology. 1997 Feb;138(2):676-82. PubMed PMID: 9003002.
6: MacGregor Schafer J, Liu H, Levenson AS, Horiguchi J, Chen Z, Jordan VC. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol. 2001 Jul;78(1):41-50. PubMed PMID: 11530283.
7: Hino M, Oda M, Yoshida A, Nakata K, Kohchi C, Nishizawa T, Inagawa H, Hori H, Makino K, Terada H, Soma G. Establishment of an in vitro model using NR8383 cells and Mycobacterium bovis Calmette-Guerin that mimics a chronic infection of Mycobacterium tuberculosis. In Vivo. 2005 Sep-Oct;19(5):821-30. PubMed PMID: 16097433.
